Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial)

Pravastatin has demonstrated anti-tumor activity in preclinical and clinical studies. This multicentric randomized double-blind placebo-controlled phase II study (NCT01418729) investigated the efficacy and safety of sorafenib + pravastatin combination on the overall survival (OS) and time to progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Riaño, Ioana, Martín, Leticia, Varela, Maria, Serrano, Trinidad, Núñez, Oscar, Mínguez, Beatriz, Rodrigues, Pedro M., Perugorria, Maria J., Banales, Jesus M., Arenas, Juan I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409102/
https://www.ncbi.nlm.nih.gov/pubmed/32674461
http://dx.doi.org/10.3390/cancers12071900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409102/
https://www.ncbi.nlm.nih.gov/pubmed/32674461
http://dx.doi.org/10.3390/cancers12071900

Ejemplares similares